The research project “(Radio)diagnostic – (Radio)therapeutic Peptides and Peptide-like Molecules for Use in Oncology” coded Ε11461 with a 7-year duration (2007-2014) is coordinated by B. A. Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Department of Nuclear Medicine & Radiology, Erasmus University MC, Rotterdam, The Netherlands, and is sponsored by Biosynthema Inc. (later on ADACAP: https://www.adacap.com/aaa-acquires-biosynthema-inc-st-louis-missouri-to-enter-radiopharmaceutical-cancer-therapeutic-market/). The cooperation aims at the development of new theranostic radiopharmaceuticals, based on peptides and peptidomimetics, for molecular targeting of cancer in human.
Major achievements of the research project “(Radio)diagnostic – (Radio)therapeutic Peptides and Peptide-like Molecules for Use in Oncology” are:
• The introduction of a new concept for the in situ stabilization of biodegradable radiopeptides, leading to
∗ Marie Curie Award at EANM’13: https://www.eanm.org/congresses-events/awards-grants/winners/
∗ Patent by EPO and USPTO: https://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2729183&KC=&FT=E&locale=en_EP
• Development of new GRPR-directed theranostic radiopharmaceuticals for targeting human cancers, leading to:
∗ Patent by EPO and USPTO: https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20201214&CC=KR&NR=20200139846A&KC=A
∗ Identification of the theranostic radioligand [68Ga]Ga/[177Lu]Lu-NeoBOMB1 for further multi-center clinical validation aiming at radiopharmaceutical development sponsored by pharmaceutical industry (ADACAP now acquired by Novartis) (ADACAP Pipeline: https://www.adacap.com/pipeline/)
Previous Page